Overview

Ramipril - Hypertension

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Primary objective: Mean values of systolic and diastolic office blood pressure Secondary objectives: Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Ramipril